Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec, Bayer CropScience Reach Screening Deal

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics has reached an agreement to use its technology to screen an undisclosed new active ingredient from Bayer CropScience.

The deal announced today calls for Berlin-based Caprotec to use its Capture Compound Mass Spectrometry technology to profile interactions of Bayer's ingredient in the relevant biological system. The technology, based on tri-functional molecules called capture compounds, can be used to define and confirm drug targets and discover off-target proteins that cause side effects.

Financial and other details were not disclosed.

In the spring, Caprotec announced it had raised $1.4 million to leverage its CCMS technology into new markets and to execute partnerships with large pharma firms.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.